Outlook Therapeutics, Inc. Common Stock
Symbol: OTLK (NASDAQ)
0.99
▼ (-1.00%) -0.010
Company Description:
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Key Stats
- Today's Open: $1.003
- Today's High: $1.029
- Today's Low: $0.981
- Today's Volume: 26.90K
- Yesterday Close: $1
- Yesterday High: $1.01
- Yesterday Low: $0.906
- Yesterday Volume: 2.63M
- Last Min Volume: 1
- Last Min High: $0.99
- Last Min Low: $0.99
- Last Min VWAP: $0.99
Company Profile
- Name: Outlook Therapeutics, Inc. Common Stock
- Website: https://www.outlooktherapeutics.com
- Listed Date: 2016-05-13
- Location: ISELIN, NJ
- Market Status: Active
- CIK Number: 0001649989
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $44.42M
- Round Lot: 100
- Outstanding Shares: 44.42M
- Asset Type: CS
RECENT FILINGS FOR OTLK
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-05 | 8-K | View |
| 2025-09-02 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-07-31 | SCHEDULE 13G | View |
| 2025-07-09 | 4 | View |
| 2025-07-09 | 3 | View |
| 2025-07-01 | 8-K | View |
| 2025-06-02 | 8-K | View |
| 2025-05-28 | SCHEDULE 13D/A | View |
| 2025-05-28 | 4 | View |
| 2025-05-23 | 424B5 | View |
| 2025-05-23 | 8-K | View |
| 2025-05-22 | 424B5 | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | 8-K | View |
| 2025-05-15 | 10-Q | View |
Latest News on OTLK